



Biotech

OP-1® Implant Package Insert

HUMANITARIAN DEVICE: OP-1 Implant is authorized by Federal law for use as an alternative to autograft in recalcitrant long bone nonunions where use of autograft is unfeasible and alternative treatments have failed. The effectiveness of this device for this use has not been demonstrated.

Caution: Federal law restricts this device to sale by or on the order of a physician.

PRODUCT DESCRIPTION:

OP-1 Implant is an osteoinductive and osteoconductive bone graft material. It is supplied in a glass vial containing one gram of the device in the form of a sterile dry powder comprised of recombinant human Osteogenic Protein 1 (OP-1 or BMP-7) and bovine bone collagen.

Self-adhesive patient labels indicating the lot number of the implant are provided for the user's convenience.

STORAGE CONDITIONS:

Store OP-1 Implant at 2-8°C.

INDICATIONS:

OP-1 Implant is indicated for use as an alternative to autograft in recalcitrant long bone non-unions where use of autograft is unfeasible and alternative treatments have failed.

CONTRAINDICATIONS:

- OP-1 Implant should not be used to treat patients who have a known hypersensitivity to the active substance or to collagen.
- OP-1 Implant should not be applied at the site of a resected tumor which is at or near the vicinity of the defect/fracture or in patients with a history of malignancy.
- OP-1 Implant should not be administered to patients who are skeletally immature (<18 years of age or no radiographic evidence of closure of epiphyses).
- OP-1 Implant should not be administered to pregnant women. The potential effects of OP-1 treatment on the human fetus have not been evaluated. Studies in rats injected with high doses of OP-1 have shown that small amounts of OP-1 will cross the placental barrier.

WARNINGS:

- Women of childbearing potential should be advised that antibody formation to products containing OP-1 and its influence on fetal development have not been completely assessed.

In an experimental animal study, OP-1 (rhBMP-7) administered to female rabbits prior to mating and during gestation elicited antibodies that crossed the placenta, exposing fetuses to anti-BMP-7 antibodies during organogenesis. The incidence of skeletal variations and malformations increased in fetuses of rabbit dams immunized to rhBMP-7 in the absence of significant maternal toxicity. The amount of increase was not above levels observed in historical controls. There are no adequate or well-controlled studies in human pregnant women. Women of childbearing potential should be warned by their surgeon of potential risk to a fetus and informed of other possible orthopedic treatments.

During clinical trials of another product containing OP-1 (OP-1 Putty), antibodies to OP-1 were measured at pretreatment and 6 weeks and 6 months post treatment. Antibodies were detected in 23 out of 24 (96%) patients treated with OP-1 Putty. No antibodies were detected in patients treated with autograft. Neutralizing antibodies were detected in 7/24 (29%) patients treated with OP-1 Putty. For six out of the seven patients, neutralizing activity was detected at 6 weeks post treatment, but not at 6 months post treatment. For the seventh patient, neutralizing activity was detected only at 6 months post treatment. The clinical significance of these antibodies is not known. The effect of maternal antibodies to OP-1 on the unborn fetus is unknown, both when the antibodies are detected during the first year following treatment and later, when the antibodies may not be detectable.

The effect of maternal antibodies to rhBMP-7, which persist for several months following device implantation, on the unborn fetus is unknown. Additionally, it is unknown whether fetal expression of BMP-7 could re-expose mothers who were previously antibody positive. Theoretically, re-exposure may elicit a more powerful immune response to BMP-7 with possible adverse consequences for the fetus. Studies in genetically altered mice indicate that BMP-7 is critical to fetal development and that a lack of BMP-7 activity may cause neonatal death or birth defects. It is not known if anti-BMP-7 antibodies may affect fetal development or the extent to which these antibodies may reduce BMP-7 activity.

- Products containing OP-1 should not be used immediately prior to or during pregnancy. Women of childbearing potential should be advised not to become pregnant for one year following treatment with products containing OP-1. Women of childbearing potential, who are treated with products containing OP-1, should have antibody testing pre-op (to develop baseline titer) and prior to attempting to become pregnant.

- The safety and effectiveness of the OP-1 Implant device in nursing mothers has not been established. It is not known if BMP-7 is excreted in human milk.

- Inappropriate use of the product such as preparing it differently than described or mixing it with materials such as graft bone or bone void fillers may produce unexpected and potentially serious adverse events that may require surgical intervention. Reported events have included altered handling characteristics, graft migration, delayed wound healing, non-union and osteolysis.

- The use of OP-1 Implant with a synthetic bone void filler may lead to a risk of increase in local inflammation, infection and occasional migration of the implanted materials and is therefore not recommended.

- The maximum human dose should not exceed 2 vials. In clinical studies treating nonunions requiring more than 2 vials, there was a higher incidence of failure.

- OP-1 Implant has no biomechanical strength to support fixation without a shared loading/stabilization adjunct (i.e. cast, instrumentation, etc.) in long bones. The following fixation methods have been utilized in clinical trials studying OP-1 Implant: cast/brace, external fixation, intramedullary rod and internal plate.

- Localized ectopic or heterotopic bone formation may occur outside of the treatment site.

- Do not use OP-1 Implant in combination with any material or product that would block access to vascularization and stem cells.

PRECAUTIONS:

- Clinical studies using OP-1 Implant were performed in patients with nonunions resulting from trauma. There are no data regarding the use of OP-1 Implant in patients with non-unions resulting from bone diseases.

- OP-1 Implant may cause an immune reaction in some patients. The safety or probable benefit of OP-1 Implant in patients with autoimmune disease has not been demonstrated.

- The effect of radiation therapy, chemotherapy, immunosuppressive or steroid therapy on the probable benefit of OP-1 Implant is not known.

- There are no data on the excretion of OP-1 in the breast milk of patients who are nursing.

- OP-1 is important in the development of the kidney. Studies have not been performed to examine the neutralizing capacity of antibodies to OP-1 or their effect in patients with impaired renal function.

- IMMUNOGENICITY:** As with all therapeutic proteins, there is a potential for immune responses to be generated against components of the OP-1 Implant. In the Tibial Nonunion clinical study, antibodies were detected to OP-1 (BMP-7) by an ELISA assay in 23/61 (38%) OP-1 treated patients and 8/61 (13%) autograft treated patients and confirmed by Western Blot analysis. The neutralizing capacity of these antibodies was not assessed. The significance of these antibodies is not known. The incidence of antibody detection is highly dependent on the sensitivity and specificity of the assay. The sensitivity of the antibody assay has not been adequately assessed and the actual incidence of antibodies could be higher. Additionally, the incidence of antibody detection may be influenced by several factors including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to OP-1 Implant with the incidence of antibodies to other products may be misleading.

- A two year rat bioassay in which approximately 17.5-70 times the equivalent maximum human dose of 2 vials of OP-1 Implant was placed under the skin, produced more cancer growths at the site of implantation of the OP-1 Implant compared to rats that had no OP-1 Implant. It is believed that this may be due to the Oppenheimer Solid State Tumor Effect, the formation of tumors at the site of implantation of inert objects under the skin in rats. This effect has not been reported in humans. Additional studies are ongoing to examine the effect of OP-1 on the growth of pre-existing tumors.

- Take care to ensure that OP-1 Implant will be contained by viable hard and soft tissue structures. Obtain adequate hemostasis before implanting OP-1 Implant to prevent the product from being displaced.

- Inadequate vascularity in the surrounding tissues may diminish the probable benefit of OP-1 Implant. Make every effort to surround the product with viable tissue.

- For single use only. Do not re-use OP-1 Implant. Discard unused product and use a new device for subsequent applications.

- Prior to use, inspect the packaging, vial and stopper for visible damage. If damage is visible, don't use the product. Retain the packaging and vial, and contact a Stryker Biotech representative.

- Do not use after the printed expiration date on the label.

ADVERSE EVENTS:

The following table is from two multicenter studies of OP-1 Implant in patients with long bone nonunions. Reported in the table are adverse events relevant to an orthopedic procedure occurring in >1% of the total treated patients. Other less frequently and related events are listed in Table 1 below. No severe adverse events were attributed to the use of OP-1 Implant.

Table 1 – Summary of Adverse Events for All Patients in the Two Long Bone Nonunion Studies

Adverse Event Description	Tibial Nonunion Study		Long Bone Nonunion Study OP-1 Implant n=29
	OP-1 Implant n=61	Autograft n=61	
Musculoskeletal			
Hardware Complication	28/61	40/61	6/29
Nonunion	7/61	4/61	5/29
Osteomyelitis	6/61	15/61	7/29
Injury as a Result of Fall	3/61	3/61	2/29
Malunion	3/61	0/61	1/29
Hardware removal	2/61	1/61	0/29
Tendonitis (patellar, Achilles)	2/61	1/61	0/29
Contracture	1/61	3/61	1/29
Fracture (other)	1/61	3/61	0/29
Fracture (tibia, fibula)	1/61	3/61	1/29
Skin and Wound			
Wound Infection	18/61	14/61	5/29
Local Inflammation, rash, redness, itching	12/61	10/61	0/29
Swelling (ankle, foot, leg)	7/61	8/61	2/29
Blisters, skin abrasions	5/61	0/61	0/29
Neural			
Pain (ankle, knee, leg)	27/61	22/61	12/29
Neuralgia (numbness)	5/61	6/61	3/29
Pain (other)	3/61	3/61	3/29
Nerve injury	2/61	2/61	0/29
Cardiovascular			
Hematoma	4/61	8/61	3/29
Anemia	4/61	5/61	1/29
Gastrointestinal			
Nausea, vomiting	18/61	19/61	3/29
Gastrointestinal upset (indigestion, constipation, diarrhea)	7/61	5/61	1/29
Systemic and Other Complications			
Fever	31/61	29/61	0/29
Normal Surgical Complications	10/61	8/61	0/29
Drug Allergy (morphine, antibiotics)	2/61	5/61	1/29

Other events include: amputation of toe, aortocoronary bypass with valve replacement, arthritis, arthroscopy, arthrosis, athlete's foot, bruising, burning sensation, cardiac complications following surgery, chondrectomy, chondromalacia, cold symptoms/upper respiratory infection, death-unrelated causes, depression, dizziness, ear infection, fatigue, gangrene, headache/migraine, incontinence, insomnia, meniscal tear, muscle spasm, muscular herniation, myositis ossificans, nosebleeds, pancreatitis, peptic ulcer, plantar fascial fibromatosis, postoperative bleeding, sciatica, skin graft, short term memory loss, shortness of breath, slow or decreased urination, stiffness, sweating, thrombophlebitis, thrombosis, urinary tract infection, weight loss, wound dehiscence, yeast infection.

Five (8%) OP-1 Implant patients reported 6 treatment related medical events, including persistent nonunion (3), erythema/swelling (2) and drainage (1).

Adverse event data has been collected from over 500 domestic and international patients treated with OP-1. Table 2 describes the incidence of cancer reported in these patients.

Table 2 – Incidence of Cancer in Patients Treated with OP-1 Worldwide

Cancer Type	Age	Sex	Time of Event Post-treatment with OP-1	Outcome
Pancreatic tumor with multiple metastases	83 yrs.	Male	3 Months	Death
Gastric carcinoma	79 yrs.	Male	9 Months	Recovered
Mantle cell lymphoma	76 yrs.	Female	29 Months	Death
Right occipital basal cell carcinoma (non-healing forehead lesion)	60 yrs.	Male	11 Months	Recovered
Recurrence of Chondrosarcoma	43 yrs.	Female	6 weeks*	Death

*Treating physician believes recurrence may have presented on thallium scan prior to treatment with OP-1.

Five patients reported the occurrence of cancer. Four of the 5 events reported were non-osteosarcomas occurring in elderly patients. A fifth event of recurring chondrosarcoma was reported in a patient with a history of chondrosarcoma. Recurrence and disease progression were considered normal for this type of cancer. The incidence of cancer in patients treated with OP-1 is less than 1% and is within the range of cancer occurrence in the general populations of the U. S. and Australia (the countries in which most patients were treated).

Eight (1.6%) out of more than 500 patients treated with OP-1 experienced 10 events related to urinary or renal systems. All 10 events were considered by the treating physicians as unrelated to study treatment and were mild to moderate in severity. No severe adverse events of this nature were reported. Events included urinary tract infection (5), slow urination (1), decreased urine output (1), urinary retention (1) and retrograde ejaculation (2). Many of these events were reported immediately post-treatment and can be attributed to catheterization during and after surgery.

PREPARATION FOR USE:

OP-1 Implant is intended to be reconstituted with sterile Sodium Chloride (NaCl) Injection, 0.9%, USP solution (saline).

- Using sterile technique, remove the vial from its packaging.

- Lift the plastic flip-top and remove the crimp from the vial.

Warning: Handle the crimp with care. The edges of the crimp are sharp and may cut or damage gloves.

- Using your thumb, pry up the edge of the stopper. Once the vacuum is broken, remove the vial stopper while holding the vial upright to prevent loss of product.

Warning: Do not insert a needle through the stopper. Puncture of the stopper with a needle may result in particles of stopper material contaminating the device.

- Carefully transfer contents of the OP-1 Implant vial to a suitable container, such as a sterile bowl.

Warning: To avoid breakage, do not tap the bottom of the vial when transferring contents.

- Utilizing a sterile syringe, carefully add 2-3 cc of sterile saline to OP-1 Implant in the container slowly and carefully. Begin with 2 cc and add saline to desired consistency. Use of more than 3 cc will result in a less cohesive product which will be difficult to handle. The reconstituted product yields 3 to 4 cc's and has the consistency of wet sand.

- Mix the saline with the product using a sterile spatula or curette.

- The product will expand to a maximum volume (~4cc) within 2 minutes. Use the product promptly after reconstituting with saline.

RECOMMENDED TECHNIQUE:

- Debride fibrous, necrotic or sclerotic tissue and, when appropriate, decorticate bone so that OP-1 Implant will directly contact viable osseous tissue.

- Provide adequate hemostasis to ensure that the material stays at the surgical site. Irrigate the surgical site as necessary, prior to placement of OP-1 Implant. Where practical, surgical manipulations to the site should be completed prior to device implantation.

- Remove the reconstituted OP-1 Implant from the container with a sterile instrument such as a spatula or curette.

- Apply OP-1 Implant to the prepared osseous tissue site. The amount of material used should approximate the size of the bone defect.

Warning: Do not use suction or irrigation directly at the implant site as this may remove particles of OP-1 Implant. Remove excess fluid by suctioning adjacent to the implant site or carefully blotting the area with a sterile sponge.

- Close soft tissues around the defect containing OP-1 Implant using suture material of choice. Closure is critical for containment and maintenance of OP-1 Implant particles in the area of the defect.

- After closure of the soft tissue around the defect, irrigate field if necessary, to remove any stray particles.

Do not place a drain directly in the implant site. Place it subcutaneously if possible.

CLINICAL EXPERIENCE:

Clinical experience with OP-1 Implant in the intended indication is summarized below. In a multicenter Tibial Nonunion Study, a subset of 14 patients with prior failed autograft was treated with OP-1 Implant. In a second multicenter Long Bone Treatment Study, 10 patients with long bone nonunions having prior failed autograft were treated with OP-1 Implant. Results are shown in Tables 3 and 4 below.

Table 3 – Tibial Nonunion Study Results- Prior Autograft Patients Only

Analysis at 9 Months	OP-1 Implant n=14	Autograft n=13
Overall	7/14	11/13
Clinical (Pain and Function)	12/14	12/13
Radiographic (Bridging in 3 views)	8/14	12/13

Table 4 – Long Bone Treatment Study Results

Analysis at 9 Months	OP-1 Implant n=10
Overall	1/10
Clinical (Pain and Function)	7/10
Radiographic (Bridging in ¾ cortices)	2/10

OP-1 Implant or a component thereof is the subject of one or more of the following patents: US Patent Nos. 4,975,526, 5,162,114, 5,171,574, 5,258,494, 5,266,683, 5,750,651, 5,863,758, 5,674,292, 6,013,856, 6,028,242, 6,261,835, 6,461,630, 6,504,079, 7,041,641, 7,078,221, 7,176,284; JP Patent Nos. 2,113,455, 2,522,568, 2,548,414, 2,845,346, 2,869,381, 2,933,867, 3,430,474, 3,483,870; AU Patent Nos. 618,357, 627,850, 628,050, 648,997, 714,963; CA Patent Nos. 1,338,663, 2,027,259, 2,223,049; AT Patent No. 0448,704; BE Patent No. 0448,704; CH Patent No. 0448,704; DE Patent Nos. P68925773.2 (0362367), P68927153.0 (0372031), P69020254.7 (0411105), P69032424.3 (0448704), P69626205.3 (0837701); DK Patent No. 0448,704; ES Patent No. 0448,704; FR Patent Nos. 0362367, 0372031, 0411105, 0448704; GB Patent Nos. 0362367, 0372031, 0411105, 0448704; GR Patent No. 0448,704; IT Patent Nos. 0362367, 0372031, 0411105, 0448704; LU Patent No. 0448,704; MC Patent No. 0968012; NL Patent No. 0448,704; SE Patent No. 0448,704. (issued/granted patents as of 03-31-08)

Manufactured by:

Stryker Biotech

35 South Street

Hopkinton, MA 01748 USA

Phone 866-476-2663

www.stryker.com

Literature Number: **V260212 Rev. 01**

Copyright © 2009 Stryker

Printed in USA